hallucinogen

Uses your system voice; voice and rate in settings.

Q194270Snapshot

≈ 15 min read

Names in other languages

  • Englishhallucinogen
  • Polskihalucynogen
  • עבריתהלוצינוגן
  • 中文致幻剂
  • 简体中文致幻剂
  • 繁體中文致幻劑
  • 中文致幻劑
  • 中文致幻剂
  • 中文致幻劑

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Hallucinogens, also known as psychedelics, entheogens, or historically as psychotomimetics, are a broad and diverse class of psychoactive drugs that can induce altered states of consciousness characterized by marked changes in perception, mood, cognition, and self-experience, along with a range of other psychological alterations. Hallucinogens are often categorized as either being psychedelics, dissociatives, or deliriants, but not all hallucinogens fall into these three classes.

Hallucinogens, also known as psychedelics, entheogens, or historically as psychotomimetics, are a broad and diverse class of psychoactive drugs that can induce altered states of consciousness characterized by marked changes in perception, mood, cognition, and self-experience, along with a range of other psychological alterations. Hallucinogens are often categorized as either being psychedelics, dissociatives, or deliriants, but not all hallucinogens fall into these three classes.

Types and examples

Types and examples of hallucinogens include the following: Psychedelics (5-HT 2A receptor agonists) like LSD, psilocybin, mescaline, and DMT Dissociatives (NMDA receptor antagonists) like ketamine, PCP, DXM, and nitrous oxide Deliriants (antimuscarinics) like scopolamine, diphenhydramine, and trihexyphenidyl κ-Opioid receptor agonists like salvinorin A, pentazocine, and levorphanol GABA A receptor agonists like muscimol and gaboxadol Oneirogens (unknown mechanism) like ibogaine and harmaline Cannabinoids (CB 1 receptor agonists) like THC, nabilone, and JWH-018 Others like carbogen, hallucinogenic bolete mushrooms, and nutmeg

Characteristics

Leo Hollister gave five criteria for classifying a drug as hallucinogenic. This definition is broad enough to include a wide range of drugs and has since been shown to encompass a number of categories of drugs with different pharmacological mechanisms and behavioral effects.

Richard Glennon has thus given an additional two criteria that narrow the category down to classical hallucinogens. Hollister's criteria for hallucinogens were as follows: in proportion to other effects, changes in thought, perception, and mood should predominate; intellectual or memory impairment should be minimal; stupor, narcosis, or excessive stimulation should not be an integral effect; autonomic nervous system side effects should be minimal; and addictive craving should be absent.

Glennon's additional criteria for classical hallucinogens are that the drugs in question must also: bind at 5-HT 2 serotonin receptors; and be recognized by animals trained to discriminate the drug DOM from vehicle.

Nomenclature and taxonomy

Most hallucinogens can be categorized based on their pharmacological mechanisms as psychedelics (which are serotonergic), dissociatives (which are generally antiglutamatergic), or deliriants (which are generally anticholinergic). However, the pharmacological mechanisms of some hallucinogens, such as salvinorin A and ibogaine, do not fit into any of those categories.

Entactogens and cannabinoids are also sometimes considered hallucinogens. Nonetheless, while the term hallucinogen is often used to refer to the broad class of drugs covered in this article, sometimes it is used to mean only classical hallucinogens (that is, psychedelics). Because of this, it is important to consult the definition given in a particular source.

Because of the multi-faceted phenomenology brought on by hallucinogens, efforts to create standardized terminology for classifying them based on their subjective effects have not succeeded to date. Classical hallucinogens or psychedelics have been described by many names.

David E. Nichols wrote in 2004: Robin Carhart-Harris and Guy Goodwin write that the term psychedelic is preferable to hallucinogen for describing classical psychedelics because of the term hallucinogen s "arguably misleading emphasis on these compounds' hallucinogenic properties." However, others such as Nichols disagree and feel that the term psychedelic should be reserved to described serotonergic psychedelics specifically as it has been historically.

Certain hallucinogens are designer drugs, such as those in the 2C and 25-NB (NBOMe) families. A designer drug is a structural or functional analog of a controlled substance (hallucinogenic or otherwise) that has been designed to mimic the pharmacological effects of the original drug while at the same time avoid being classified as illegal (by specification as a research chemical) and/or avoid detection in standard drug tests.

Effects by type

Different classes of hallucinogens have different mechanisms of action and effects.

Psychedelics

. Psychedelics, also known as serotonergic psychedelics or classical hallucinogens, are serotonin 5-HT 2A receptor agonists with hallucinogenic effects.

Despite several attempts that have been made, starting in the 19th and 20th centuries, to define common phenomenological structures (i.e., patterns of experience) brought on by classical psychedelics, a universally accepted taxonomy does not yet exist. A prominent element of psychedelic experiences is visual alteration.

Psychedelic visual alteration often includes spontaneous formation of complex flowing geometric visual patterning in the visual field. When the eyes are open, the visual alteration is overlaid onto the objects and spaces in the physical environment; when the eyes are closed the visual alteration is seen in the "inner world" behind the eyelids.

These visual effects increase in complexity with higher dosages, and also when the eyes are closed. The visual alteration does not normally constitute hallucinations, because the person undergoing the experience can still distinguish between real and internally generated visual phenomena, though in some cases, true hallucinations are present.

More rarely, psychedelic experiences can include complex hallucinations of objects, animals, people, or even whole landscapes. A number of studies by Roland R. Griffiths and other researchers have concluded that high doses of psilocybin and other classic psychedelics trigger mystical experiences in most research participants.

Mystical experiences have been measured by a number of psychometric scales, including the Hood Mysticism Scale, the Spiritual Transcendence Scale, and the Mystical Experience Questionnaire. The revised version of the Mystical Experience Questionnaire, for example, asks participants about four dimensions of their experience, namely the "mystical" quality, positive mood such as the experience of amazement, the loss of the usual sense of time and space, and the sense that the experience cannot be adequately conveyed through words.

The questions on the "mystical" quality in turn probe multiple aspects: the sense of "pure" being, the sense of unity with one's surroundings, the sense that what one experienced was real, and the sense of sacredness. Some researchers have questioned the interpretation of the results from these studies and whether the framework and terminology of mysticism are appropriate in a scientific context, while other researchers have responded to those criticisms and argued descriptions of mystical experiences are compatible with a scientific worldview.

Link R. Swanson divides overarching scientific frameworks for understanding psychedelic experiences into two waves. In the first wave, encompassing nineteenth- and twentieth-century frameworks, he includes model psychosis theory (the psychotomimetic paradigm), filtration theory, and psychoanalytic theory.

In the second wave of theories, encompassing twenty-first-century frameworks, Swanson includes entropic brain theory, integrated information theory, and predictive processing. It is from the paradigm of filtration theory that the term psychedelic derives.

Aldous Huxley and Humphrey Osmond applied the pre-existing ideas of filtration theory, which held that the brain filters what enters into consciousness, to explain psychedelic experiences; Huxley believed that the brain was filtering reality itself and that psychedelics granted conscious access to "Mind at Large", whereas Osmond believed that the brain was filtering aspects of the mind out of consciousness. Swanson writes that Osmond's view seems "less radical, more compatible with materialist science, and less epistemically and ontologically committed" than Huxley's.

Oneirogens

Oneirogens like ibogaine and harmaline are said to produce oneirophrenia, or a dream-like state of consciousness. This state is unique and different from other hallucinogens. They increase fantasy, vividity of visual imagery, spontaneity of thought content, long-term memory recall, and closure of unresolved emotional conflicts, among other effects.

Overt hallucinogenic effects like with serotonergic psychedelics, such as formal alterations or deterioration of thinking, depersonalization, psychotic-like effects such as delusions, and perceptual changes of one's environment, are absent.

Others

. Other hallucinogens, including κ-opioid receptor agonists such as Salvia divinorum or salvinorin A, GABA A receptor agonists like Amanita muscaria or muscimol, and cannabinoids like cannabis or Δ 9 -tetrahydrocannabinol (THC), have their own varieties of hallucinogenic effects.

In addition, hallucinogenic bolete mushrooms have been associated with other types of hallucinations, such as Lilliputian hallucinations. Aminochromes like adrenochrome and adrenolutin have been claimed to be hallucinogenic by Abram Hoffer, Humphry Osmond and colleagues, although the validity of these claims is disputed.

Uncured tobacco has been reported to produce deliriant-esque effects due to its intoxicatingly high levels of nicotine.

Psychotomimetic paradigm

While early researchers believed certain hallucinogens mimicked the effects of schizophrenia, it has since been discovered that some hallucinogens resemble endogenous psychoses more than others. PCP and ketamine more closely resemble endogenous psychoses because they reproduce both positive and negative symptoms of psychoses, while psilocybin and related hallucinogens typically produce effects resembling only the positive symptoms of schizophrenia.

While the serotonergic psychedelics (LSD, psilocybin, mescaline, etc.) do produce subjective effects distinct from NMDA antagonist dissociatives (PCP, ketamine, dextrorphan), there is clear overlap in the mental processes that these drugs affect and research has discovered that there is overlap in the mechanisms by which both these types of hallucinogens mimic psychotic symptoms. One double-blind study examining the differences between DMT and ketamine hypothesized that classically psychedelic drugs most resemble paranoid schizophrenia while dissociative drugs best mimicked catatonic subtypes or otherwise undifferentiated schizophrenia.

The researchers stated that their findings supported the view that "a heterogeneous disorder like schizophrenia is unlikely to be modeled accurately by a single pharmacological agent."

Adverse effects

No clear connection has been made between serotonergic psychedelics and organic brain damage. Hallucinogen-induced psychotic disorder (HIPD) is a psychotic disorder caused by hallucinogens and has an occurrence rate of 0.6% in randomized controlled trials.

Hallucinogen persisting perception disorder (HPPD) is a diagnosed condition wherein certain visual effects of hallucinogenic drugs persist for a long time after taking it, and is most often found in frequent users of hallucinogens. A large epidemiological study in the U.S. found that other than personality disorders and other substance use disorders, lifetime hallucinogen use was not associated with other mental disorders, and that risk of developing a hallucinogen use disorder was very low.

Chemistry

Hallucinogens can be divided into different classes with different mechanisms of action and structural scaffolds. Serotonergic psychedelics can be divided into three main chemical classes: tryptamines (such as psilocin and DMT), ergolines (such as LSD), and phenethylamines (such as mescaline). Tryptamines closely resemble serotonin chemically.

Other types of hallucinogens belong to other structural classes, for instance arylcyclohexylamines like ketamine and phencyclidine (PCP) being the most major structural group in the case of dissociatives.

Traditional religious and shamanic use

Historically, hallucinogens have been commonly used in religious or shamanic rituals. In this context they are referred to as entheogens, and are used to facilitate healing, divination, communication with spirits, and coming-of-age ceremonies.

Evidence exists for the use of entheogens in prehistoric times, as well as in numerous ancient cultures, including Ancient Egyptian, Mycenaean, Ancient Greek, Vedic, Maya, Inca and Aztec cultures. The Upper Amazon is home to the strongest extant entheogenic tradition; the Urarina of the Peruvian Amazon, for instance, continue to practice an elaborate system of ayahuasca shamanism, coupled with an animistic belief system.

Shamans consume hallucinogenic substances in order to induce a trance. Once in this trance, shamans believe that they are able to communicate with the spirit world, and can see what is causing their patients' illness. The Aguaruna of Peru believe that many illnesses are caused by the darts of sorcerers.

Under the influence of yaji, a hallucinogenic drink, Aguaruna shamans try to discover and remove the darts from their patients. In the 1970s, Frida G. Surawicz and Richard Banta published a review of two case studies where hallucinogenic drug use appeared to play a role in "delusions of being changed into a wolf" (sometimes referred to as "lycanthropy," or being a "werewolf").

They described a patient whose delusion was thought to be caused by an altered state of consciousness "brought on by LSD and strychnine and continued casual marijuana use." The review was published in the Canadian Psychiatric Association Journal.

While both central cases described white male patients from contemporary Appalachia, Surawicz and Banta generalized their conclusions about a link between hallucinogens and "lycanthropy," based on historical accounts that reference myriad types of pharmacologically-similar drug-use alongside descriptions of "lycanthropes."

Early scientific investigations

In an 1860 book, the mycologist Mordecai Cubitt Cooke differentiated a class of drugs roughly corresponding to hallucinogens from opiates, and in 1924 the toxicologist Louis Lewin described hallucinogens in depth under the name phantastica. From the 1920s on, work in psychopharmacology and ethnobotany resulted in more detailed knowledge of various hallucinogens.

In 1943, Albert Hofmann discovered the hallucinogenic properties of lysergic acid diethylamide (LSD), which raised the prospect of hallucinogens becoming more broadly available.

Hallucinogens after World War II

After World War II there was an explosion of interest in hallucinogenic drugs in psychiatry, owing mainly to the invention of LSD. Interest in the drugs tended to focus on either the potential for psychotherapeutic applications of the drugs (see psychedelic psychotherapy), or on the use of hallucinogens to produce a "controlled psychosis", in order to understand psychotic disorders such as schizophrenia.

By 1951, more than 100 articles on LSD had appeared in medical journals, and by 1961, the number had increased to more than 1,000 articles. At the beginning of the 1950s, the existence of hallucinogenic drugs was virtually unknown to the general public in the West. However this soon changed as several influential figures were introduced to the hallucinogenic experience.

Aldous Huxley's 1953 essay The Doors of Perception, describing his experiences with mescaline, and R. Gordon Wasson's 1957 Life magazine article ("Seeking the Magic Mushroom") brought the topic into the public limelight. In the early 1960s, counterculture icons such as Jerry Garcia, Timothy Leary, Allen Ginsberg and Ken Kesey advocated the drugs for their psychedelic effects, and a large subculture of psychedelic drug users was spawned.

Psychedelic drugs played a major role in catalyzing the major social changes initiated in the 1960s. As a result of the growing popularity of LSD and disdain for the hippies with whom it was heavily associated, LSD was banned in the United States in 1967. This greatly reduced the clinical research about LSD, although limited experiments continued to take place, such as those conducted by Reese Jones in San Francisco.

As early as the 1960s, research into the medicinal properties of LSD was being conducted. According to pharmacologist David E. Nichols, "Savage et al. (1962) provided the earliest report of efficacy for a hallucinogen in OCD, where after two doses of LSD, a patient who suffered from depression and violent obsessive sexual thoughts experienced dramatic and permanent improvement".

Starting in the mid-20th century, psychedelic drugs have received extensive attention in the Western world. They have been and are being explored as potential therapeutic agents in treating alcoholism, and other forms of drug addiction.

Etymology

The word hallucinogen is derived from the word hallucination. The term hallucinate dates back to around 1595–1605, and is derived from the Latin hallūcinātus, the past participle of (h)allūcināri, meaning "to wander in the mind."

In the U.S., classical hallucinogens (psychedelics) are in the most strictly prohibited class of drugs, known as Schedule 1 drugs. This classification was created for drugs that meet the three following characteristics: 1) they have no currently accepted medical use, 2) there is a lack of safety for their use under medical supervision, and 3) they have a high potential for abuse.

However, pharmacologist David E. Nichols argues that hallucinogens were placed in this class for political rather than scientific reasons. In 2006, Albert Hofmann, the chemist who discovered LSD, said he believed LSD could be valuable when used in a medical rather than recreational context, and said it should be regulated in the same way as morphine rather than more strictly.

The Netherlands previously allowed psilocybin mushrooms to be sold, but in October 2007 the Dutch government moved to ban their sale following several widely publicized incidents involving tourists. In November 2020, Oregon became the first U.S. state to both decriminalize psilocybin and legalize it for therapeutic use, after Ballot Measure 109 passed.

Usage prevalence

A September 2025 national survey of American adults conducted by the RAND Corporation found that the most commonly used hallucinogens and related drugs (past-year use) were psilocybin (4.3%), MDMA or MDA (1.8%), Amanita muscaria (1.3%), ketamine (1.3%), LSD (1.1%), DMT (0.84%), mescaline (0.53%), 2C-B (0.46%), Salvia divinorum (0.43%), ibogaine or iboga (0.36%), and 5-MeO-DMT (0.30%). The survey also found that about 3.7% of adults had microdosed in the past year, with the most frequent drugs being psilocybin, MDMA, and LSD.

See also

Closed-eye visualization Hallucinogenic plants in Chinese herbals List of investigational hallucinogens and entactogens List of hallucinogens Out-of-body experience Psychedelia Psychedelic experience Psychonautics Psychopharmacology Trip killer Trip report Visual perception

References

Hallucinogens - Wikipedia Massviews Analysis (Wikipedia Page Views of Individual Hallucinogens)

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376678294 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.